Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Authors

Maged Khalil MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

2022

Published In/Presented At

Jean L. Grem et al.,

Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. JCO 40, 106-106(2022).

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Lehigh Valley Topper Cancer Institute

Document Type

Article